Quantcast

Latest Management of cancer Stories

2014-04-16 12:29:58

The Canadian Partnership Against Cancer announces $13 million in funding for partner organisations TORONTO, April 16, 2014 /CNW/ - Every person who is living with cancer is unique, and so is that person's cancer journey. The person-centred perspective in cancer care is driven by the needs, values and priorities of the person receiving the care. The Canadian Partnership Against Cancer is pleased to announce $13 million in funding to provinces, territories and cancer organizations...

2014-04-15 23:09:00

The cancer information website Cancer Monthly says bladder cancer patients who took Actos should not wait to seek legal advice, despite drug maker’s plans to appeal a federal jury’s ruling. Raleigh, NC (PRWEB) April 15, 2014 The makers of the diabetes drug Actos say they will appeal last week’s award of $9 billion in punitive damages to a man who claims that Actos caused his bladder cancer, (1) (Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No....

2014-04-13 23:01:22

Days after a federal jury announced a $9 billion dollar judgment against the drug’s manufacturers, Cancer Monthly is encouraging bladder cancer patients to know their rights. Raleigh, NC (PRWEB) April 13, 2014 The Japanese manufacturer of the diabetes drug Actos and its partner firm, Eli Lilly & Co., have been ordered to pay $9 billion to Terrence Allen, who was diagnosed with bladder cancer after taking Actos. (Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc.,...

2014-04-11 12:07:26

A group of researchers in China and the US have successfully created a 3D model of a cancerous tumor using a 3D printer. The model, which consists of a scaffold of fibrous proteins coated in cervical cancer cells, has provided a realistic 3D representation of a tumor's environment and could help in the discovery of new drugs and cast new light on how tumors develop, grow and spread throughout the body. The results of the study have been published today, 11 April, in IOP Publishing's...

2014-04-10 12:10:29

Preventing lung cancers from metastasizing to other parts of the body could provide benefit for patients against the leading cause of cancer death Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen). The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the...

2014-04-10 08:28:33

DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-04-09 23:25:06

Biochemical testing suggests a pair of proteins can find and monitor bladder cancer better than standard techniques. Raleigh, NC (PRWEB) April 09, 2014 A team of Egyptian biochemists say angiogenin and clusterin – two proteins vital to certain cellular processes – could make bladder cancer diagnosis more accurate and treatments more effective. Click here to read details on the study which has just been posted on the Cancer Monthly website. Researchers with the Faculty of...

2014-04-09 08:28:15

SANTA ROSA, Calif., April 9, 2014 /PRNewswire/ -- A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma. Conducted by researchers at the Cancer Research Laboratory at Indiana University Health, Indiana University School of Medicine, the preclinical study showed that honokiol (HonoPure®, EcoNugenics, Santa Rosa, CA) inhibited two highly aggressive renal cell carcinoma (RCC) cell lines....

2014-04-08 12:32:28

Champions TumorGrafts(TM) Provide Accurate Predictions of Treatments' Efficacy in 81 Percent of Evaluated Patients with Advanced Sarcoma HACKENSACK, N.J., April 8, 2014 /PRNewswire/ -- Data published in Cancer show the use of personalized patient-derived xenografts, or mouse avatars, accurately predicted treatment efficacy in all evaluated patients with advanced sarcoma. The results support the predictive capabilities of Champions TumorGrafts®, developed by Champions Oncology (OTC:...

2014-04-08 08:30:56

Creative innovator to advance Epic's CTC technology for rapid analysis of cancer for patient matching to clinical trials, therapeutic selection and resistance monitoring SAN DIEGO, April 8, 2014 /PRNewswire/ -- Epic Sciences announced today the appointment of Pascal Bamford, Ph.D. as vice president of product development. Dr. Bamford has more than 15 years of experience in developing complex, automated diagnostic systems for digital pathology. Prior to joining Epic Sciences, Dr....


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related